ES2270120T3 - Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. - Google Patents
Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. Download PDFInfo
- Publication number
- ES2270120T3 ES2270120T3 ES03773451T ES03773451T ES2270120T3 ES 2270120 T3 ES2270120 T3 ES 2270120T3 ES 03773451 T ES03773451 T ES 03773451T ES 03773451 T ES03773451 T ES 03773451T ES 2270120 T3 ES2270120 T3 ES 2270120T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- sequence
- protein
- seq
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 37
- 241000700605 Viruses Species 0.000 title abstract description 30
- 208000015181 infectious disease Diseases 0.000 title abstract description 26
- 208000004729 Feline Leukemia Diseases 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 27
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 13
- 101710172711 Structural protein Proteins 0.000 claims abstract description 13
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 11
- 241000282324 Felis Species 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 119
- 108020004414 DNA Proteins 0.000 claims description 84
- 230000014509 gene expression Effects 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 65
- 241000714165 Feline leukemia virus Species 0.000 claims description 60
- 241000282326 Felis catus Species 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 239000013612 plasmid Substances 0.000 claims description 23
- 230000003053 immunization Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000003505 mutagenic effect Effects 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 7
- 239000003471 mutagenic agent Substances 0.000 claims description 7
- 231100000707 mutagenic chemical Toxicity 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 231100000219 mutagenic Toxicity 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000021601 lentivirus infection Diseases 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 description 33
- 101800001271 Surface protein Proteins 0.000 description 31
- 238000005457 optimization Methods 0.000 description 31
- 238000002255 vaccination Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 239000012634 fragment Substances 0.000 description 22
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 238000002649 immunization Methods 0.000 description 18
- 239000013598 vector Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000256135 Chironomus thummi Species 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 101800000504 3C-like protease Proteins 0.000 description 7
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 7
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 101800000607 p15 Proteins 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 5
- 241000608867 Leucogenes Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000388 leucogen effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 102100025055 NTF2-related export protein 1 Human genes 0.000 description 2
- 102400001093 PAK-2p27 Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000030414 genetic transfer Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000020847 Body for Life Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710109927 Tail assembly protein GT Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10244863 | 2002-09-23 | ||
| DE10244863 | 2002-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2270120T3 true ES2270120T3 (es) | 2007-04-01 |
Family
ID=32038184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03773451T Expired - Lifetime ES2270120T3 (es) | 2002-09-23 | 2003-09-19 | Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7915035B2 (enExample) |
| EP (1) | EP1553977B1 (enExample) |
| JP (1) | JP4411213B2 (enExample) |
| AT (1) | ATE335507T1 (enExample) |
| AU (1) | AU2003281917A1 (enExample) |
| DE (2) | DE50304603D1 (enExample) |
| DK (1) | DK1553977T3 (enExample) |
| ES (1) | ES2270120T3 (enExample) |
| WO (1) | WO2004028562A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0901593D0 (en) * | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| RS58289B1 (sr) * | 2011-07-20 | 2019-03-29 | Merial Ltd | Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije |
| EP3706789A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Feline calicivirus vaccine |
| CA3080427A1 (en) * | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Feline leukemia virus vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| DE19648625A1 (de) * | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
| US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
| SE9803099D0 (sv) * | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
| WO2003031470A2 (de) * | 2001-10-02 | 2003-04-17 | Mologen Ag | Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose |
-
2003
- 2003-09-19 DE DE50304603T patent/DE50304603D1/de not_active Expired - Lifetime
- 2003-09-19 DK DK03773451T patent/DK1553977T3/da active
- 2003-09-19 EP EP03773451A patent/EP1553977B1/de not_active Expired - Lifetime
- 2003-09-19 AT AT03773451T patent/ATE335507T1/de active
- 2003-09-19 WO PCT/DE2003/003179 patent/WO2004028562A2/de not_active Ceased
- 2003-09-19 ES ES03773451T patent/ES2270120T3/es not_active Expired - Lifetime
- 2003-09-19 JP JP2004538747A patent/JP4411213B2/ja not_active Expired - Fee Related
- 2003-09-19 DE DE10393824T patent/DE10393824D2/de not_active Expired - Fee Related
- 2003-09-19 AU AU2003281917A patent/AU2003281917A1/en not_active Abandoned
- 2003-09-23 US US10/528,748 patent/US7915035B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1553977B1 (de) | 2006-08-09 |
| WO2004028562A2 (de) | 2004-04-08 |
| JP2006511211A (ja) | 2006-04-06 |
| ATE335507T1 (de) | 2006-09-15 |
| US20060240034A1 (en) | 2006-10-26 |
| JP4411213B2 (ja) | 2010-02-10 |
| DK1553977T3 (da) | 2006-11-27 |
| AU2003281917A1 (en) | 2004-04-19 |
| DE10393824D2 (de) | 2005-08-11 |
| EP1553977A2 (de) | 2005-07-20 |
| DE50304603D1 (de) | 2006-09-21 |
| AU2003281917A8 (en) | 2004-04-19 |
| US7915035B2 (en) | 2011-03-29 |
| WO2004028562A3 (de) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7548902B2 (ja) | アフリカ豚熱ウイルスワクチン | |
| KR102581951B1 (ko) | B형 간염 바이러스 코어 단백질 및 표면 항원 단백질 및 이를 포함하는 백신 | |
| US6465438B1 (en) | Nucleic acid vaccination for parvoviral infections | |
| US20040228842A1 (en) | Compositions and methods for cytomegalovirus treatment | |
| KR101891195B1 (ko) | 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법 | |
| KR102742526B1 (ko) | 암 백신 및 이를 이용하는 치료 방법 | |
| EA023892B1 (ru) | Иммуногенные белки вируса человеческой папилломы и способы их применения | |
| Golshani et al. | Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen | |
| ES2363079T3 (es) | Vacuna que comprende gp120 y nef y/o tat para la inmunización contra el vih. | |
| EP1017283B1 (en) | Polynucleotide vaccine formulations | |
| ES2270120T3 (es) | Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. | |
| ES2298829T3 (es) | Agente para el tratamiento de infecciones por leishmania. | |
| ES2282156T3 (es) | Vacuna de acido nucleico. | |
| US8465748B2 (en) | Vaccine compositions and methods containing an immunogen derived from equine arteritis virus | |
| CA2336992A1 (en) | Polynucleotide vaccine formulations | |
| CN101379078A (zh) | 爱泼斯坦-巴尔病毒相关疾病的治疗 | |
| US20250134979A1 (en) | Dna vaccine against leishmaniasis | |
| Li et al. | CpG DNA enhances the immune responses elicited by the DNA vaccine against foot-and-mouth disease virus in guinea pigs | |
| AU764010B2 (en) | Polynucleotide vaccine formulations | |
| Moynier et al. | Characterization of humoral immune responses induced by immunization with plasmid DNA expressing HIV-1 Nef accessory protein | |
| IT201900016736A1 (it) | Antigeni fusi alla proteina Profilin-like di Toxoplasma Gondii (PFTG) e loro uso nella vaccinazione preventiva e terapeutica. | |
| HK1108115A1 (en) | Sars vaccine based on replicative vaccinia virus vector | |
| HK1108115B (en) | Sars vaccine based on replicative vaccinia virus vector |